BioSpace News Archive

CASI Pharmaceuticals, Inc. today reported that Juventas Cell Therapy Ltd. (“Juventas”) has completed a Series C financing round through which it raised more than RMB410 million (approximately $63 million (USD)).

Research Findings for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and RELISTOR® (methylnaltrexone bromide) Will be Presented

Viking Therapeutics, Inc. today announced that preclinical data from a series of novel dual agonists of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors will be presented at ObesityWeek 2021, the annual meeting of The Obesity Society.

Castle Biosciences, Inc. today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2021, after the close of market on Monday, Nov. 8, 2021.

Bristol Myers Squibb (NYSE:BMY) today announced that it has changed the timing of its previously announced earnings conference call. The Company will now host a conference call to discuss results for the third quarter of 2021 on Wednesday, October 27, 2021 at 10:00 a.m. ET .

Taysha Gene Therapies Announces Publication of Positive Proof-of-Concept Preclinical Data for an AAV-mediated UBE3A Gene Replacement Approach Demonstrating Therapeutic Potential for The Treatment of Angelman Syndrome in the Journal JCI Insight

EpiEndo Pharmaceuticals ( www.epiendo.com ) is pleased to announce that it is the recipient of this year’s Rising Star Award at the Swedish American Life Sciences Summit (SALSS).

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that it has received funding from the Bill & Melinda Gates Foundation to support the demonstration of its ability to deliver a human immunodeficiency virus (“HIV”) preventative therapeutic

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with various complement mediated diseases.

BioInvent International today announces the appointment of the renowned immunotherapy expert Alexander Eggermont MD, PhD, as a member of its Scientific Advisory Board.